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HOX genes are transcription factors that play important roles in body patterning and many cellular pro-
cesses during embryonic, fetal, and adult development. Given their important function in normal tissues, it
is reasonable to assume that abnormal expression of HOX genes in adults could lead to serious diseases
such as cancer. Our previous study reported HOXB5 to be signiﬁcantly up-regulated in breast cancer, and
its expression was found to be associated with tumor cell proliferation and invasion. Furthermore, the
epidermal growth factor receptor (EGFR), a cellular tyrosine kinase that plays an important role in breast
cancer progression, was found signiﬁcantly up-regulated by HOXB5 in ER-positive breast cancer cells. In
the present study, we demonstrated that HOXB5 regulates EGFR expression at the transcriptional level by
directly binding to its promoter region and promotes phosphorylation of EGFR as well as its downstream
effectors. Patients with ER-positive breast cancer, having high co-expression of HOXB5 and EGFR, had poor
prognosis than those with low expression. Knockdown studies validated a key role played by EGFR in the
HOXB5-induced invasion of breast cancer cells. These results suggest that targeting EGFR could be an
effective strategy to treat breast cancer in patients with high HOXB5 expression.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
HOX genes are highly conserved homeobox genes that encode
transcriptional factors required for normal development and dif-
ferentiation [1,2]. They are not only expressed during embryonic
development, but also continue to be expressed in the adult, and
regulate various cellular pathways such as cell proliferation, cell
adhesion, migration, and apoptosis [3]. Recently, deregulated HOX
gene expressionwas observed in different cancers, including breast
cancer, and has been implicated in tumorigenesis, cancer progres-
sion, and metastasis [4,5].
HOXB5 is involved in a variety of developmental processes
including lung, gut, and neural crest development [6e8]; its
expression is also found to be associatedwith several types of cancer
[9e13]. Additionally, our previous studies have demonstrated that
HOXB5 contributes to cell proliferation, invasion, and tamoxifengrowth factor receptor; ChIP,
tastasis free survival; MEK,
Inc. This is an open access article uresistance of breast cancer cells, and that high expression of HOXB5
is prognostic of poor breast cancer survival [14,15]. We have shown
earlier that epidermal growth factor receptor (EGFR) gene expres-
sion is regulated by either overexpression or knockdown of HOXB5
in ER-positive breast cancer cells [15]. However, the mechanism
of HOXB5-mediated regulation of EGFR expression and the rele-
vance of its contribution to the invasive phenotypes of HOXB5-
overexpressing cells has not been elucidated yet.
In this study, we explored the role of HOXB5 in the regulation of
EGFR expression and signaling activation in HOXB5-overexpressing
MCF7 cells. Our results show that EGFR is a direct target of tran-
scriptional regulation by HOXB5 and the resulting HOXB5-
mediated EGFR activation plays an important role in enhancing
the invasive phenotype of the breast cancer cells.
2. Methods
2.1. Cell lines and cell culture
MCF7 and HEK293T cells were cultured in Dulbecco's modiﬁed
eagle's medium (DMEM; Welgene Inc., Daegu, Korea) supple-
mented with 10% of fetal bovine serum (FBS, Welgene) and 1
antibiotic-antimycotic solution (Welgene) at 37 C in annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Transcriptional regulation of EGFR by HOXB5. (A) HOXB5 and EGFR expression levels were examined in MCF7 stable cells expressing HOXB5 (MCF7_HOXB5#1, #2, #3, and
#4) and MCF7 control cells harboring empty vector (MCF7_empty#1 and #2). The fold change shown in the graph was quantitated by real-time PCR. The data are represented as
mean ± SEM. *p < 0.001 vs. MCF7_empty#1. (B) The mean value of HOXB5 and EGFR expression level from three independent MDA-MB-231 stable cells expressing HOXB5 (MDA-
MB-231_HOXB5#1, #2, and #3). MDA-MB-231 cells harboring empty vector were used as controls. (C) Schematic diagram and sequence analysis of the 1.1 kb upstream sequence of
EGFR. Putative HOX core consensus binding elements (TAAT/ATTA/TTAT/ATAA/TTAC) are marked with pink lines and written in red upper case italicized letters in the sequence. The
transcription start site (TSS) is written in upper case bold. The primers for cloning F1 and F2 fragments are indicated by red arrows. The promoter regions for the validation of ChIP-
PCR (site 1 to 4) are colored orange, purple, green, and blue, respectively. The forward and reverse primers for each site are marked by arrows of same color. (D) Dual luciferase
reporter assay for EGFR F1, F2, and control vector in HEK-293T and MCF7 cells. (E) Effect of HOXB5 overexpression on the promoter activity of EGFR F1 and F2 fragments. pGL3-EGFR
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lines was performed as described previously [15].
2.2. RNA isolation and RT-PCR
Total RNA was isolated from the cultured cells using TRIzol re-
agent (Invitrogen) according to the manufacturer's instructions.
cDNA was generated using ImProm-II™ Reverse Transcriptase
(Promega, Madison, WI, USA). PCR was performed in replicates
using Taq polymerase (Bioneer, Daejeon, Korea). Quantitative PCR
was performed using SYBR green PCR Master Mix (Applied Bio-
systems, Carlsbad, CA, USA) on an ABI7300 real-time PCR system
(Applied Biosystems). The PCR primers used in this study are listed
in Table S1.
2.3. Dual luciferase assay
Dual luciferase assay was performed as described previously
[16]. Genomic DNA fragments of the EGFR promoter region (EGFR
F1 and EGFR F2; Fig. 1) were ampliﬁed using Pfu polymerase (Sol-
Gent, Daejeon, Korea) and cloned into the pGL3-Basic vector
(Promega) using KpnI and SmaI sites. Restriction enzyme sites were
incorporated into the primers (Table S1). Control pGL3-Basic vector
or the pGL3-EGFR constructs were transfected into HEK293T or
MCF7 cells with the Renilla luciferase vector (pRL Renilla luciferase
control) using Attractene transfection reagent (Qiagen). Promoter
activity was measured using the Dual-Luciferase Reporter Assay
System (Promega) after 48 h of transfection and normalized using
Renilla luciferase activity. Effect of HOXB5 on the promoter activity
was measured in MCF7 cells after the co-transfection of Renilla
luciferase vector and pGL3-EGFR vector with either control pcDNA3
or pcDNA3-HOXB5. Assays were conducted in triplicate for each
experiment. Similar results were obtained from three independent
experiments.
2.4. Chromatin immunoprecipitation (ChIP) analysis
ChIP was performed with chromatin prepared from MCF7 cells.
The cells were ﬁxed in 37% formaldehyde for 15min, and then
quenched with glycine to a ﬁnal concentration of 0.125M for
10min. Sonication was performed using Sonics Vibra-Cell™ to
obtain approximately 500e1000 bp DNA fragments. Antibodies
against HOXB5 (sc-81099; Santa Cruz) were used along with IgG
(sc-2025; Santa Cruz). DNA, puriﬁed from immunoprecipitated
chromatin and from direct input, was used for PCR. The primer
sequences for ChIP-PCR are shown in Table S1.
2.5. Western blotting
Western blot analysis was performed as previously described
[15]. Antibodies against EGFR (#4267; Cell Signaling Technology,
Inc. MA, USA), phosphor-EGFR (Tyr1068; #3777; Cell Signaling), Src
(#2110; Cell Signaling), phosphor-Src (Tyr416; #6943; Cell
Signaling), MEK1/2 (#4694; Cell Signaling), phosphor-MEK1/2
(Ser217-221; #9154; Cell Signaling), ERK1/2 (#9102; Cell
Signaling), phosphor-ERK1/2 (T202/T204; #9101, Cell Signaling),
Akt1 (#2967; Cell Signaling), phosphor-Akt (Ser473; #4058; Cell
Signaling), phosphor-Akt (Thr308; #9275; Cell Signaling), and b-
actin (ab6276; Abcam, Cambridge, UK) were used to detect eachpromoter constructs (pGL3-EGFR-F1 and F2) were co-transfected with effector plasmid con
Luciferase activity was measured after 48 h of transfection and normalized to that of Ren
*p< 0.001 vs. empty control. (F) ChIP-PCR results show HOXB5 binding to EGFR upstream re
precipitated with HOXB5 antibody or control IgG. ChIP-ed DNA was ampliﬁed with speciﬁ
legend, the reader is referred to the Web version of this article.)protein.2.6. Effect of EGFR knockdown on tumor cell viability and invasion
Cell viability assay was performed by using the Cell Counting
Kit-8 (CCK-8) following the manufacturer's instruction (Dojindo
Molecular Technologies, Inc., Kumamoto, Japan). Invasion assay
was performed using Matrigel™ (BD) as described previously [15],
in HOXB5-overexpressing and control MCF7 cells. For knockdown
study, the cells were transfected with 50 nM EGFR siRNA (#L-
003114-00-0005; Dharmacon, Waltham, MA, USA) or non-speciﬁc
siRNA (#D-001810-10-05; Dharmacon) using G-Fectin reagent
(Genolution, Seoul, Korea).2.7. Statistical analysis
For all experiments, a minimum of three independent biological
replicates were analyzed for quantitation. Data are expressed as the
mean value with standard error. Statistical differences were
determined by Student's t-test. A p-value of <0.05 was considered
statistically signiﬁcant. The online Kaplan-Meier plotter (http://
kmplot.com) was used to analyze the clinical signiﬁcance of
HOXB5 and EGFR expression in patients with breast cancer.3. Results
3.1. Transcriptional regulation of EGFR by HOXB5 in MCF7 breast
cancer cells
Our previous studies showed that EGFR is one of genes regu-
lated by HOXB5 in breast cancer cells [15]. To investigate the mo-
lecular mechanism underlying HOXB5-mediated EGFR regulation,
we ﬁrst monitored mRNA expression level of EGFR in four inde-
pendent clones of MCF7 cell lines stably expressing HOXB5.
Compared to the levels in two MCF7 cell lines harboring empty
vector, EGFR expression in HOXB5-overexpressing MCF7 clones
was signiﬁcantly high (Fig. 1A). In contrast, overexpression of
HOXB5 in ER-negative MDA-MB-231 cells had no effect on EGFR
expression (Fig. 1B). We then examined the effect of HOXB5 on the
promoter activity of EGFR by performing luciferase reporter assay.
Two different-sized genomic fragments, EGFR-F1 spanning 1132
to þ91 bp and EGFR-F2 spanning 457 to þ91 bp, contained a
series of putative HOX-binding sites and had strong promoter ac-
tivity both in HEK-293TandMCF7 cells (Fig.1C and D). The ability of
the larger fragment, EGFR-F1, to drive expression of the reporter
was signiﬁcantly greater than that of the shorter fragment, EGFR-F2
(Fig. 1D), indicating that the performance increased proportionally
with the number of HOX-binding sites. Importantly, the transcrip-
tional activity of the reporter, driven by EGFR-F1 or EGFR-F2, was
clearly induced by exogenous HOXB5 expression (Fig. 1E). The
direct binding of HOXB5 to the promoter region of EGFRwas further
conﬁrmed by ChIP analysis using MCF7 cells (stably overexpressing
HOXB5) and control MCF7 cells (harboring an empty vector).
HOXB5 binding was observed in sites 1 to 4, with site 2 showing the
strongest binding and site 4 the weakest, probably depending on
the number of HOX-binding sites (Fig. 1F). This data demonstrates
that binding of HOXB5 to the EGFR promoter correlates with the
ability of HOXB5 to regulate EGFR gene expression.taining HOXB5 or empty vector. HOXB5 mRNA expression was conﬁrmed by RT-PCR.
illa luciferase, used as an internal control. The data are represented as mean ± SEM.
gions. Chromatin, isolated from MCF7 cells overexpressing HOXB5 or empty vector, was
c primer sets shown in (C). (For interpretation of the references to color in this ﬁgure
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overexpressing cells
EGFR expression is known to be associated with aggressive
phenotypes of breast cancer through the activation of downstream
signaling pathways that regulate various cellular processes, such as
cell proliferation, differentiation, and adhesion [17]. Here, we
examined HOXB5-mediated activation of EGFR and its effect on
downstream signaling pathways using two clones of MCF7 cells,
stably expressing HOXB5, and two clones of control cells (Fig. 2).
Consistent with the ﬁndings at the mRNA level, the total protein
and phosphorylation levels of EGFR were found to be up-regulated
in HOXB5-overexpressing cells. Activated EGFR enhanced Src and
MEK/ERK signaling, but did not affect Akt phosphorylation. Our
data imply that HOXB5 overexpression induces EGFR activation and
potentially affects the downstream Ras/Raf/MEK/ERK pathway
rather than the Ras/PI3K/PTEN/Akt pathway.
3.3. Contribution of EGFR to cancer cell invasion in HOXB5-
overexpressing cells
EGFR is known to promote migration and invasion of cancer
cells [17e19]. Since HOXB5 was also shown to have a role in inva-
sion [15], we conﬁrmed and extended these ﬁndings to examine
the contribution of EGFR to the invasion of HOXB5-overexpressing
breast cancer cells. The mRNA expression of HOXB5 and EGFR were
much higher in the MCF7 cells stably overexpressing HOXB5,
compared to that in the control cells, and the transfection of EGFR
siRNA in both cells speciﬁcally suppressed EGFR expression
(Fig. 3A). Invasion assays showed that the numbers of invaded cellsFig. 2. Western blot analyses of EGFR and downstream signaling pathway activation.
Protein extracts, isolated fromMCF7 cells overexpressing HOXB5 (MCF7_HOXB5#2 and
MCF7_HOXB5#3) and control MCF7 cells harboring empty vector (MCF7_empty#1 and
MCF7_empty#2), were used for the assay. Antibodies used were EGFR, p-EGFR, Src, p-
Src, MEK1/2, p-MEK1/2, ERK, p-ERK1/2, AKT1, p-AKT1, and beta-actin.increased signiﬁcantly in HOXB5-overexpressing MCF7 cells
compared to that in the control cells harboring empty vector
(Fig. 3B). In the EGFR-siRNA knockdown cells, the numbers of cells
invaded was signiﬁcantly decreased, even below the basal levels
seen in vector control cells (Fig. 3B). Unlike the effect on invasion,
EGFR silencing in HOXB5 overexpressing cells did not affect cell
viability (Fig. 3C). These results suggest that the invasive properties
seen in HOXB5-overexpressing cells were largely dependent on
EGFR up-regulation and its downstream signaling activities.
3.4. Clinical signiﬁcance of HOXB5 and EGFR in breast cancer
We had previously reported that high expression of HOXB5 is
linked to poor prognosis in breast cancer [15]. In this study, the
Kaplan-Meier method was employed to examine the prognostic
value of combined HOXB5/EGFR expression. Importantly, we found
that HOXB5 and EGFR are more likely to be associated with poor
clinical outcome in ER-positive breast cancers when both genes are
overexpressed simultaneously, as compared to when HOXB5 or
EGFR is overexpressed alone (Fig. 4AeB). In the ER-negative patient
group, co-expression of HOXB5 and EGFR appear to have a poorer
prognosis, but the number of patients was relatively small and did
not show a signiﬁcant difference (Fig. 4CeD). In addition, based on
our results, it is likely that EGFR overexpression in ER-negative
breast cancer is independent of HOXB5. Collectively, these results
indicate that HOXB5-induced up-regulation of EGFR in ER-positive
breast cancer may contribute to accelerate tumor progression, due
to which high expression of both HOXB5 and EGFR has a negative
synergistic effect on patient outcome.
4. Discussion
In this study, we have demonstrated that HOXB5, in breast
cancer cells, regulates EGFR at the transcriptional level by binding
to the EGFR promoter region. Activation of EGFR then leads to the
propagation of downstream signal that promotes cancer develop-
ment. EGFR is the key player that mediates the effect of HOXB5 on
cancer cell invasion.
In recent years, deregulated HOX gene expression has been
observed in different human tumors [4,5]. Several groups,
including our own, have identiﬁed many HOX genes with altered
expression, especially in breast cancer [14,20e22]. HOXB5 is one of
the genes up-regulated in breast cancer and associated with its
progression [14,15]. Similar to HOXB5, HOXB7 overexpression has
also been reported to promote breast tumorigenesis and render
MCF7 cells resistant to tamoxifen through the activation of EGFR
pathway [23]. These observations suggest functional redundancy
among the HOX genes.
EGFR overexpression in breast cancer is known to be associated
with large tumor size, poor differentiation, and poor clinical
outcome, and is, therefore, one of the ﬁrst identiﬁed targets of
antitumor agents [17,24,25]. However, it remains difﬁcult to deﬁne
the group of patients who might beneﬁt from a speciﬁc drug.
Therefore, development of speciﬁc biomarkers for categorizing
patients according to their molecular characterization is absolutely
necessary to proceed towards personalized medicine. According to
our studies, overexpression of HOXB5 and the resulting EGFR up-
regulation appears to play an important role in ER-positive breast
cancer rather than ER-negative breast cancer. Our previous study
showing HOX gene expression pattern in different breast cancer
cell lines indicated that HOXB5 is predominantly expressed in ER-
positive breast cancer cell lines [14]. As shown in this study, the
expression of EGFR was regulated by HOXB5 overexpression or
silencing in ER-positive cells such asMCF7 and T47D [15], but not in
ER-negative MDA-MB-231 cells. The prognosis of HOXB5 and EGFR
Fig. 3. Contribution of EGFR to the cell invasion and viability of HOXB5-overexpressing breast cancer cells. HOXB5-overexpressing and control MCF7 cells were transfected with
either siEGFR or nonspeciﬁc siCon and were used for RT-PCR and invasion assay. (A) HOXB5 and EGFR mRNA expression, with or without siRNA knockdown of EGFR; beta-actin used
as control. (B) Matrigel invasion assay of MCF7 cells expressing HOXB5 or empty vector, with or without knockdown of EGFR. The number of invading cells was counted after
staining with DAPI. (C) Cell viability of HOXB5-overexpressing MCF7 cells, with or without knockdown of EGFR.
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Fig. 4. The prognostic signiﬁcance of HOXB5 and EGFR expression in breast cancer. (AeB) Kaplan-Meier analysis of distant metastasis-free survival (DMFS) in patients with breast
cancer. The red and black lines indicate high and low expression of HOXB5/EGFR in all patients with breast cancer (A) and with ER-positive tumors (B). (CeD) Overall survival (C)
and distant metastasis-free survival (D) in ER-negative breast cancers. The red and black lines indicate high and low expression of HOXB5 and EGFR. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
J.-Y. Lee et al. / Biochemical and Biophysical Research Communications 503 (2018) 2924e2930 2929was also signiﬁcantly worse in ER-positive patients than ER-
negative patients, although the impact of the two genes in the
ER-negative patient population as a prognostic factor can be
concluded with the accumulation of more extensive data. Taken
together, our results show a signiﬁcant role of EGFR in HOXB5-
mediated biological pathways in breast cancer cells, thereby sug-
gesting that EGFR-targeted anti-tumor agents may be valuable to
ER-positive breast cancer patients with high co-expression of
HOXB5 and EGFR.
In conclusion, our data enhance the understanding of the mo-
lecular mechanisms underlying HOXB5-mediated pathways in
breast cancer, and also provide an evidence for the causal rela-
tionship between HOXB5 and EGFR in cancer cell invasion.Author contributions
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